In the last trading session, 62.71 million Evaxion Biotech A/S ADR (NASDAQ:EVAX) shares changed hands as the company’s beta touched -0.28. With the company’s per share price at $3.27 changed hands at $0.87 or 36.25% during last session, the market valuation stood at $3.83M. EVAX’s last price was a discount, traded about -624.77% off its 52-week high of $23.70. The share price had its 52-week low at $2.22, which suggests the last value was 32.11% up since then. When we look at Evaxion Biotech A/S ADR’s average trading volume, we note the 10-day average is 7.05 million shares, with the 3-month average coming to 1.25 million.
Analysts gave the Evaxion Biotech A/S ADR (EVAX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended EVAX as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Evaxion Biotech A/S ADR’s EPS for the current quarter is expected to be -0.15.
Evaxion Biotech A/S ADR (NASDAQ:EVAX) trade information
Instantly EVAX was in green as seen at the end of in last trading. With action -25.17%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -22.64%, with the 5-day performance at -25.17% in the red. However, in the 30-day time frame, Evaxion Biotech A/S ADR (NASDAQ:EVAX) is -29.24% down. Looking at the short shares, we see there were 0.1 million shares sold at short interest cover period of 1.07 days.
Evaxion Biotech A/S ADR (EVAX) estimates and forecasts
Data shows that the Evaxion Biotech A/S ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -75.32% over the past 6 months, a 89.38% in annual growth rate that is considerably higher than the industry average of 15.90%.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 1.66M. 1 analysts are of the opinion that Evaxion Biotech A/S ADR’s revenue for the current quarter will be 3.2M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 6,174.51%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -18.88%. The 2025 estimates are for Evaxion Biotech A/S ADR earnings to increase by 89.93%.
